According to Custom Market Insights (CMI), The Global Multi Cancer Early Detection Market Size was valued at USD USD 800.23 million in 2021 and is estimated to reach USD 3186.8 Million by the end of 2030 at a CAGR of approximately 16.5% during the forecast period 2022-2030.
Multi-cancer early detection is a diagnostic test intended to detect the various types of cancer in the human body. Multi-cancer early detection test is carried out by taking various samples such as blood, liquid biopsy, gene, LTD, and others. This diagnostic test helps physicians examine the risk of developing the multiplication of cancer cells inside a blood vessel, epidermis, colon, lungs, throat, and other body parts. In response, MCED is intended to find tumors in the body.
Browse the full “Multi Cancer Early Detection Market Size, Trends and Insights By Type (Liquid Biopsy, Gene Panel, LDT, Others), By End User (Hospitals, Diagnostic Laboratories, Others), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share Outlook, and Forecast 2023–2032” report at https://www.custommarketinsights.com/report/multi-cancer-early-detection/
Market dynamics
Drivers
The Growing use of multi-cancer early detection in hospitals and laboratory sectors will aid the market growth. The multi-cancer early detection market has witnessed a high potential growth due to increased awareness, and government focus on the early detection test has driven the market growth. For instance, WHO supports the Member States in developing and implementing cancer early diagnosis and screening programs, according to assessed feasibility and cost-effectiveness of screening, and with adequate capacity to avoid delays in diagnosis and cancer treatment. The overall demand for the multi-cancer early detection testing market will be expected to grow exponentially.
Restraints
However, some primary screening of multi-cancer early detection tests may cause potential adverse health effects such as tears in the lining of the epidermis and colon. Furthermore, the expensive testing of the multi-cancer early detection market is restraining the market’s overall growth. In addition, high production costs and the requirement of advance machinery will slow down the market.
Opportunities
The rise in smoking, drinking, obesity, elevated cholesterol levels, and exposure to harmful radiation are the key factors contributing to the death of people every year. For instance, according to an article by WHO in February 2022, cancer deaths accounted for nearly 10 million deaths in 2020 or nearly one in six deaths. These factors are making people more conscious about multi-cancer early detection tests, which has enhanced the market’s potential sales of the market; thus offering the most lucrative opportunities.
Challenges
Over the forecast period, the false negative result while screening may occur, and maintenance of the machinery by no trained clinical staff, inadequate or even absent calibrations and quality controls, lack of cost-effectiveness because of an increased number of different types of cancer, and more expensive tests and many others will act as a challenging factor for the growth of multi cancer early detection market.
Get Free Sample Copy @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=18256
Report Highlights
Depending upon the type, the multi-cancer early detection market is segmented into liquid biopsy, gene panel, LDT, and others.
The gene panel, LDT, and other segments dominated the market in 2021 and are expected to grow with 80% of the total market share over the forecast period. The gene panel segment mainly deals with hereditary cancers where various organizations in developed and developing countries have initiated the multi-cancer early detection test. For instance, an article published by National Cancer Institute (NIH) recommended cancer genetic testing projects, and a clinical trial has been acknowledged. These factors are boosting the overall market growth in the outlook period.
According to an article published by National Cancer Institute, several Companies with MCED tests currently under study claim that they can detect anywhere from two or three cancer types up to as many as 50. These factors capture the market growth during the forecast period.
Key Players
- Grail, LLC (Illumina, Inc.)
- Exact Sciences Corporation.
- Foundation Medicine, Inc.
- AnchorDx
- Guardant Health, Inc.
- Burning Rock Biotech Limited
- GENECAST
- Laboratory for Advanced Medicine, Inc.
- Singlera Genomics Inc.
Table of Contents: https://www.custommarketinsights.com/report/multi-cancer-early-detection/#table-of-contents
About Us:
Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.
Custom Market Insights provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey.
Contact Us:
USA Corporate Office
CMI Consulting LLC
1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702
Sales & Support +1 801 639 9061
Email : support@custommarketinsights.com
Website : https://www.custommarketinsights.com/
Comments
0 comment